Apogee Therapeutics (APGE) is in focus after releasing interim Phase 1b data for its asthma drug candidate zumilokibart, highlighting robust FeNO biomarker suppression, a clean safety profile, and ...

AMD gains AI share as DC revenue hit $4.3B, MI300 adoption rises, MI400 targets cloud inference at premium valuation. Read ...

Blue collar autonomy is an unadvertised hero of the AoT™ revolution. Critical infrastructure monitoring is an area that is ...

Ameren trades near 20x forward P/E with the lowest yield, strong CAPEX, data center growth, and regulatory risk priced in.

Brokerage estimates point to TCS' modest revenue expansion, stable demand in key verticals and close scrutiny of deal wins, ...

The clinical-stage biotech could see its shares plummet should there be any clinical setback.

Discover how the Middle East is set to invest over $100 billion annually by 2026 in sectors like energy, AI, and healthcare, ...

The October-December period was marked by some crucial strategic announcements by the IT services behemoth, including its ...

As water turns toxic, tunnels flood, and sanitation workers die in sewers, a deeper failure surfaces—absence of underground ...

Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal ...

The average fee paid to bankers for IPOs rose to 1.86 per cent of a deal's value, versus 1.67 per cent a year earlier, ...

One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for ...